Mercado de terapia con bacteriófagos en Asia y el Pacífico, por objetivo (Escherichia coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, otros), tipo (lítico, lisogénico), base (cultivo de caldo estéril, base de gelatina soluble en agua), aplicación (disentería bacteriana, infecciones de la piel y la mucosa nasal, infección cutánea supurativa, infecciones pulmonares y pleurales, infecciones de heridas posoperatorias, otras), vía de administración (oral, parenteral, rectal, dérmica, otras), usuario final (hospitales, clínicas especializadas, investigación académica e institutos, otros), canal de distribución (licitación directa, distribuidores externos), país (Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, Vietnam, resto de Asia y el Pacífico), tendencias de la industria y pronóstico hasta 2028.
Análisis y perspectivas del mercado: mercado de terapia con bacteriófagos en Asia y el Pacífico
Se espera que el mercado de terapia con bacteriófagos de Asia y el Pacífico gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 7,1% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 13,30 millones para 2028.
Los bacteriófagos, también llamados fagos o virus bacterianos, son cualquier grupo de virus que infectan bacterias para tratar infecciones bacterianas. Los bacteriófagos podrían usarse como una alternativa a los antibióticos cuando las bacterias desarrollan resistencia. Los bacteriófagos son mucho más específicos que los antibióticos . Por lo general, son inofensivos no solo para el organismo huésped sino también para otras bacterias beneficiosas, como la microbiota intestinal, lo que reduce las posibilidades de infecciones oportunistas. La creciente prevalencia de infecciones resistentes a los antibióticos y el aumento de las actividades de investigación y desarrollo son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico. Sin embargo, los altos costos asociados con la terapia y la escasez de profesionales capacitados son los factores que se espera que limiten el crecimiento del mercado en el período de pronóstico.
Se espera que la presencia de nuevos fármacos en desarrollo, las iniciativas estratégicas de los actores del mercado y el aumento del gasto en el sector de la salud proporcionen una oportunidad de crecimiento lucrativa para el mercado. Por otro lado, la limitación de la terapia con bacteriófagos y la falta de directrices regulatorias adecuadas actúan como un desafío importante para el crecimiento del mercado.
El informe de mercado de la terapia con bacteriófagos proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un informe de analista. Nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de terapia con bacteriófagos en Asia y el Pacífico
The bacteriophages therapy market is segmented on the basis of target, type, base, application, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of target, the Asia-Pacific bacteriophages therapy market is segmented into Escherichia coli, Staphylococcus, streptococcus, pseudomonas, salmonella, others. In 2021 the staphylococcus segment is expected to dominate the market due to its limited effect on the site of infection, most common bacterial species causing infection, and a variety of diseases that need proper treatment for the infection to get a cure.
- On the basis of type, the Asia-Pacific bacteriophages therapy market is segmented into lytic and lysogenic. In 2021, the lytic segment is expected to dominate the market because of the instant recovery and therapeutic effect provided by this type of lytic bacteriophage.
- On the basis of the base, the Asia-Pacific bacteriophages therapy market is segmented into sterile broth culture, water-soluble jelly base. In 2021, sterile broth culture is expected to dominate the market due to high sensitivity with suitable media and more specificity towards the bacteriophages.
- On the basis of application, the Asia-Pacific bacteriophages therapy market is segmented into bacterial dysentery, infections of the skin and nasal mucosa, suppurative skin infection, lung and pleural infections, postoperative wound infections, others. In 2021, the postoperative wound segment is expected to dominate the market due to the rising prevalence of diabetes and increasing patients' inclination towards surgery.
- On the basis of route of administration, the Asia-Pacific bacteriophages therapy market is segmented into oral, parenteral, rectal, dermal, others. In 2021, the oral segment is expected to dominate the market due to no need for sterile precautions and minimal danger of acute drug reaction.
- On the basis of end-user, the Asia-Pacific bacteriophages therapy market is segmented into hospitals, specialty clinics, academic research and institutes, others. In 2021, the hospital's segment is expected to dominate the market due to facility management and improved processes through staff interaction.
- On the basis of distribution channels, the Asia-Pacific bacteriophages therapy market is segmented into direct sales and third-party distributors. In 2021, the direct tender segment is expected to dominate the market due to price certainty and better accountability.
Bacteriophages Therapy Market Country Level Analysis
The bacteriophages therapy market is analyzed, and market size information is provided on the basis of target, type, base, application, route of administration, end-user, and distribution channel
The countries covered in the bacteriophage therapy market report are Japan, China, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.
The staphylococcus segment in the Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 due to its limited effect on the site of infection, most common bacterial species causing infection, and variety of diseases that need proper treatment for the infection to get cure. China is expected to dominate the Asia-pacific bacteriophage therapy market due to rapidly evolving biotechnology infrastructure and supportive government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Private Sector Funding And Technological Advancements Are Boosting The Market Growth Of Bacteriophages Therapy.
The bacteriophages therapy market also provides you with detailed market analysis for every country's growth in the bacteriophage therapy industry with drugs sales, the impact of advancement, technology, and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for the historical period 2011 to 2019.
Competitive Landscape and Bacteriophages Therapy Market Share Analysis
Bacteriophages therapy market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the bacteriophages therapy market.
The major companies operating in the global bacteriophages therapy market are Phagelux, Inc., MICREOS, ATCC, Armata pharmaceuticals Inc. among others.
Many product launches and agreements are also initiated by companies worldwide, which are also accelerating the bacteriophage therapy market.
For instance,
- En abril de 2020, Phagelux, Inc. anunció que la empresa había iniciado múltiples colaboraciones comerciales, como la colaboración europea de ventas, marketing y desarrollo de productos con DCM para su línea de biopesticidas AgriPhage, entre otras. Esto ha ayudado a la empresa a explorar y desarrollar bacteriófagos de próxima generación de forma completa.
- En junio de 2021, Adaptive Phage Therapeutics anunció el inicio de un estudio de fase 1/2 de terapia con bacteriófagos (Phage Bank) para evaluar la seguridad, la tolerabilidad y la eficacia de tratamientos personalizados y específicos con bacteriófagos ("fagos") en pacientes con infección del tracto urinario (ITU). Esto ha ayudado a la empresa a desarrollar un tratamiento novedoso para infecciones bacterianas resistentes a múltiples fármacos.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de la terapia con bacteriófagos, lo que también proporciona el beneficio para que una organización mejore su oferta de terapia con bacteriófagos.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TAREGET LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES MODEL
4.2 PESTEL ANALYSIS
5 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: REGULATIONS
5.1 THE U.S. REGULATORY GUIDELINES FOR BACTERIOPHAGES
5.2 EUROPE REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.3 JAPAN REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.4 AUSTRALIA REGULATORY GUIDELINE FOR BACTERIOPHAGE
6 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: REGIONAL SUMMARY
7 RESEARCH AND DEVELOPMENT ANALYSIS: ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET
7.1 PIPELINE ANALYSIS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF ANTIBIOTIC-RESISTANT INFECTIONS
8.1.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.1.3 INCREASING GOVERNMENT FUNDING
8.1.4 INCREASING PRIVATE SECTOR FUNDING
8.1.5 TECHNOLOGICAL ADVANCEMENTS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH BACTERIOPHAGE THERAPY
8.2.2 LACK OF SKILLED PROFESSIONALS
8.2.3 SIDE-EFFECTS OF BACTERIOPHAGE THERAPY
8.2.4 AVAILABILITY OF ALTERNATIVE THERAPIES FOR ANTIBIOTIC RESISTANCE
8.3 OPPORTUNITIES
8.3.1 PRESENCE OF NOVEL PIPELINE DRUGS
8.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
8.3.3 INCREASING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 LIMITATIONS OF BACTERIOPHAGE THERAPY
8.4.2 LACK OF PROPER REGULATORY GUIDELINES
9 IMPACT OF COVID-19 ON ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET
9.1 IMPACT ON THE PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY
9.4 STRATEGIC INITIATIVES BY MANUFACTURERS
9.5 CONCLUSION
10 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET
10.1 OVERVIEW
10.2 STAPHYLOCOCCUS
10.3 ESCHERICHIA COLI
10.4 PSEUDOMONAS
10.5 STREPTOCOCCUS
10.6 SALMONELLA
10.7 OTHERS
11 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TYPE
11.1 OVERVIEW
11.2 LYTIC
11.3 LYSOGENIC
12 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY BASE
12.1 OVERVIEW
12.2 STERILE BROTH CULTURE
12.3 WATER-SOLUBLE JELLY BASE
13 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 POSTOPERATIVE WOUND INFECTIONS
13.3 INFECTIONS OF SKIN AND NASAL MUCOSA
13.4 BACTERIAL DYSENTERY
13.5 SUPPURATIVE SKIN INFECTIONS
13.6 LUNG AND PLEURAL INFECTION
13.7 OTHERS
14 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 LIQUID
14.2.2 TABLET
14.3 DERMAL
14.4 PARENTERAL
14.4.1 INTRAVENOUSLY
14.4.2 INTRAPLEURAL INJECTIONS
14.5 OTHERS
15 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECILAITY CLINICS
15.4 ACADEMIC RESEARCH & INSTITUTES
15.5 OTHERS
6 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTORS
17 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY REGION
17.1 ASIA-PACIFIC
17.1.1 CHINA
17.1.2 JAPAN
17.1.3 INDIA
17.1.4 AUSTRALIA
17.1.5 SOUTH KOREA
17.1.6 SINGAPORE
17.1.7 REST OF ASIA-PACIFIC
18 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 MICROGEN
20.1.1 COMPANY SNAPSHOT
20.1.2 COMPANY SHARE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 ADAPTIVE PHAGE THERAPEUTICS
20.2.1 COMPANY SNAPSHOT
20.2.2 COMPANY SHARE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 PHAGELUX,INC
20.3.1 COMPANY SNAPSHOT
20.3.2 COMPANY SHARE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 LOCUS BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ATCC
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 INTRALYTIX, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENTS
20.7 MICREOS
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 PYLUM
20.8.1 COMPANY SNAPSHOT
20.8.2 TECHNOLOGY PORTFOLIO
20.8.3 RECENT DEVELOPMENTS
20.9 FIXED-PHAGE LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 ARMATA PHARMACEUTICALS, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 ARTHUR ANDREW MEDICAL
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 CYTOPHAGE TECHNOLOGIES INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 ENBIOTIX, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENTS
20.14 INTODEWORLD, INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 NEXTBIOTICS
20.15.1 COMPANY SNAPSHOT
20.15.2 TECHNOLOGY PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 PHERECYDES PHARMA
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tablas
TABLE 1 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 2 ASIA PACIFIC STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 ASIA PACIFIC ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 ASIA PACIFIC PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA PACIFIC STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA PACIFIC SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA PACIFIC OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 ASIA PACIFIC LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA PACIFIC LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 12 ASIA PACIFIC STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 15 ASIA PACIFIC POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 ASIA PACIFIC OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA PACIFIC PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA PACIFIC ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 CHINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 47 CHINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 CHINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 49 CHINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 50 CHINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 51 CHINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 52 CHINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 CHINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 CHINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 56 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 JAPAN BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 58 JAPAN BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 JAPAN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 60 JAPAN ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 JAPAN PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 62 JAPAN BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 JAPAN BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 INDIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 65 INDIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 INDIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 67 INDIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 68 INDIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 INDIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 INDIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 INDIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 72 INDIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 73 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 74 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 76 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 77 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 AUSTRALIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 79 AUSTRALIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 80 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 83 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 85 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 86 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 87 SOUTH KOREA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 88 SOUTH KOREA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 89 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 90 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 91 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 92 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 94 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 SINGAPORE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 SINGAPORE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 100 REST OF ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET : ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET
FIGURE 15 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020
FIGURE 16 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)
FIGURE 17 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)
FIGURE 18 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020
FIGURE 20 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 21 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020
FIGURE 24 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)
FIGURE 25 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)
FIGURE 26 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020
FIGURE 28 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 29 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 33 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020
FIGURE 36 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 37 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 41 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 44 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 45 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 48 ASIA PACIFIC BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
